Cited 0 times in Scipus Cited Count

Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial

DC Field Value Language
dc.contributor.authorKim, CY-
dc.contributor.authorPaek, SH-
dc.contributor.authorNam, DH-
dc.contributor.authorChang, JH-
dc.contributor.authorHong, YK-
dc.contributor.authorKim, JH-
dc.contributor.authorKim, OL-
dc.contributor.authorKim, SH-
dc.date.accessioned2022-10-24T05:53:39Z-
dc.date.available2022-10-24T05:53:39Z-
dc.date.issued2020-
dc.identifier.issn0167-594X-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/22352-
dc.description.abstractBACKGROUND: Tumor treating fields (TTFields) are anti-mitotic, non-invasive loco-regional cancer therapy comprising low intensity, intermediate frequency alternating electric fields. TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We report on Korean newly diagnosed GBM patients who participated in the EF-14 trial.

METHODS: Thirty-nine participants of the EF-14 trial were enrolled at 8 sites in South Korea. Patients (24 TTFields/TMZ; 14 TMZ alone) received: TTFields (200 kHz) for > 18 h/day; TMZ at 120-150 mg for 5 days per a 28 day cycle. Safety and efficacy were assessed.

RESULTS: Patient baseline characteristics were balanced in the 2 arms and the mean age was 52.1 years, 66.7% were male with a mean KPS of 90. Safety incidence was comparable between the 2 arms. In the TTFields/TMZ arm, 30% suffered from skin irritation versus 52% in the entire study population. No TTFields-related serious adverse events were reported. The median progression-free survival (PFS) in the TTFields/TMZ arm was 6.2 months (95% CI 4.2-12.2) versus 4.2 (95% CI 1.9-11.2) with TMZ alone (p = 0.67). Median overall survival was 27.2 months (95% CI 21-NA) with TTFields/TMZ versus 15.2 months (95% CI 7.5-24.1; HR 0.27, p = 0.01) with TMZ alone.

CONCLUSION: Median OS and 1- and 2-year survival rates were higher with TTFields/TMZ and similar to the entire EF-14 population. About 30% of patients reported skin irritation, a lower rate than seen in the entire EF-14 population. These results demonstrate the efficacy and safety of TTFields in Korean newly diagnosed glioblastoma patients.

CLINICAL TRIALS: Clinicaltrials.gov Identifier: NCT00916409.
-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Agents, Alkylating-
dc.subject.MESHAsians-
dc.subject.MESHBrain Neoplasms-
dc.subject.MESHElectric Stimulation Therapy-
dc.subject.MESHFemale-
dc.subject.MESHGlioblastoma-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHProgression-Free Survival-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHTemozolomide-
dc.subject.MESHYoung Adult-
dc.titleTumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial-
dc.typeArticle-
dc.identifier.pmid32020470-
dc.subject.keywordGlioblastoma-
dc.subject.keywordKorean GBM patients-
dc.subject.keywordTumor treating fields-
dc.contributor.affiliatedAuthorKim, SH-
dc.type.localJournal Papers-
dc.identifier.doi10.1007/s11060-019-03361-2-
dc.citation.titleJournal of neuro-oncology-
dc.citation.volume146-
dc.citation.number3-
dc.citation.date2020-
dc.citation.startPage399-
dc.citation.endPage406-
dc.identifier.bibliographicCitationJournal of neuro-oncology, 146(3). : 399-406, 2020-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1573-7373-
dc.relation.journalidJ00167594X-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Neurosurgery
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse